Strategies in the Management of Alemtuzumab-Related Side Effects
Authors:
- Anders ÖsterborgAÖAnders Österborg
- Claes KarlssonCKClaes Karlsson
- Jeanette LundinJLJeanette Lundin
- Eva KimbyEKEva Kimby
- Håkan MellstedtHMHåkan Mellstedt
- 1 April 2006
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 33, 29-35
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL)Journal of Clinical Oncology, 2004
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002
- Current and developing chemotherapy for CLL.Medical Oncology, 2002
- A Personal History of the CAMPATH-1H AntibodyMedical Oncology, 2002
- Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patientsBlood, 2001
- Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011Journal of Clinical Oncology, 2001
- Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)Blood, 1999
- Infections in Patients with Chronic Lymphocytic Leukemia Treated with FludarabineAnnals of Internal Medicine, 1998
- Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.Journal of Clinical Investigation, 1996